Insider Trading By Ex-FDA Official Puts Spotlight On Agency Practices
This article was originally published in The Tan Sheet & The Rose Sheet
After Office of Generic Drugs Deputy Director Gordon Johnston left FDA, he joined GPhA and 'tricked' a former colleague into sharing info on generic Lovenox on behalf of a hedge fund he was secretly working for, SEC says.
You may also be interested in...
Jeff George, global head of Sandoz, talks about enoxaparin, a commitment to quality manufacturing, and investing in differentiated products.
Insider Trading Bull's-Eye: FDA Chemist Charged With Using Agency's DARRTS NDA Tracking System For Improper Trades
A criminal complaint charges Cheng Yi Liang with trading in the securities of five companies based on the status of their new drug applications, gaining more than $2 million.
Agency's five criteria for determining "sameness" of generic enoxaparin to Sanofi-Aventis's low molecular weight heparin could serve as guideposts for future biosimilar approvals.